| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Phosphoinositide-3-kinase-interacting protein 1, Kringle domain-containing protein HGFL, PIK3IP1, HGFL |
| Entrez GeneID | 113791 |
| WB Predicted band size | 28.2kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This PIK3IP1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 178-207 amino acids from the C-terminal region of human PIK3IP1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于PIK3IP1抗体的虚构参考文献示例(实际文献请通过学术数据库查询)：
1. **文献名称**：*PIK3IP1 regulates T cell immunity by inhibiting PI3K/AKT signaling*
**作者**：Chen L, et al.
**摘要**：本研究利用PIK3IP1特异性抗体，通过免疫沉淀和Western blot分析，揭示了PIK3IP1通过结合p110亚基抑制PI3K/AKT通路活性，从而调控T细胞活化和自身免疫疾病的发展。
2. **文献名称**：*Monoclonal antibody-based detection of PIK3IP1 in tumor microenvironment*
**作者**：Wang X, et al.
**摘要**：开发了一种高亲和力抗PIK3IP1单克隆抗体，应用于免疫组化及流式细胞术，发现PIK3IP1在多种实体瘤中表达下调，且低表达与患者预后不良相关，提示其可能的抑癌功能。
3. **文献名称**：*PIK3IP1 modulates insulin sensitivity via PI3K pathway interaction*
**作者**：Kim S, et al.
**摘要**：通过抗体介导的蛋白沉默实验，证实PIK3IP1在肝脏组织中负调控胰岛素-PI3K信号通路，其缺失导致糖代谢异常，为代谢综合征治疗提供了新靶点。
4. **文献名称**：*A novel PIK3IP1 antibody reveals its dynamic expression during B cell development*
**作者**：Müller R, et al.
**摘要**：利用新型兔源多克隆抗体，结合免疫荧光技术，首次报道了PIK3IP1在B细胞分化过程中的动态表达模式，并证明其参与调控B细胞受体信号传导的负反馈机制。
(注：以上内容为模拟生成，实际研究请参考PubMed、Google Scholar等平台。)
The PIK3IP1 (Phosphoinositide-3-Kinase Interacting Protein 1) antibody is a research tool designed to detect and study the PIK3IP1 protein, a negative regulator of the PI3K (phosphatidylinositol 3-kinase) signaling pathway. PIK3IP1 interacts with the p110 catalytic subunit of PI3K, inhibiting its activity and modulating the PI3K/AKT/mTOR axis, a critical pathway involved in cell growth, survival, and metabolism. Dysregulation of this pathway is linked to cancers, immune disorders, and metabolic diseases, making PIK3IP1 a potential therapeutic or diagnostic target.
Antibodies targeting PIK3IP1 are widely used in techniques like Western blotting, immunohistochemistry (IHC), and flow cytometry to assess protein expression, localization, and function in various tissues or cell types. Studies have shown that PIK3IP1 is highly expressed in immune cells, particularly regulatory T cells (Tregs), where it may suppress excessive immune activation. Reduced PIK3IP1 levels have been observed in hepatocellular carcinoma, breast cancer, and inflammatory conditions, correlating with enhanced PI3K signaling and disease progression.
These antibodies are typically validated for specificity using knockout (KO) controls or siRNA-mediated silencing. Commercial PIK3IP1 antibodies are available in monoclonal and polyclonal forms, often raised in hosts like rabbits or mice. Researchers utilize them to explore PIK3IP1's role in immune homeostasis, tumorigenesis, and metabolic regulation, aiming to uncover its clinical relevance in precision medicine.
×
